P. Claver Kayumba

Pierre Claver KAYUMBA holds a Master's Degree and a PhD in Pharmaceutical Sciences from Ghent University in Belgium. In the context of having a skilled workforce in health supply chain management in East Africa, he is currently coordinating both academic and continuous professional development programs at the EAC Regional Center of Excellence for Vaccines, Immunization and Health Supply Chain Management (RCE-VIHSCM) hosted by the University of Rwanda. He is the Chair of the Board of Directors for Rwanda Medical Supply Ltd, a Rwandan Government Owned Company, created to ensure effective supply chain through timely availability of good quality health commodities and cost-efficiency. He is also a board Director for the Rwandan National Industrial Research Development (NIRDA). Previously, he has been the Founder Director General and Deputy Director General in charge of Medical Procurement and Production of Rwanda Biomedical Center (RBC). He was mandated to implement health policies related to diseases prevention and control, availability of commodities and technologies and biomedical research. As an academician and researcher, Pierre Claver KAYUMBA is also leading a GlaxosmithKline funded research assessing the quality of antimicrobials circulating on the Rwandan market, he is supervising PhD researches in the area of quality, availability, affordability of essential medicines and the area of immunization supply chain systems re-design. He has been the Deputy Dean for the School of Medicine and Pharmacy. He has been also Vice Dean in charge of Post-Graduate Studies in Medicine, Pharmacy and Clinical Psychology. He has published and still publishing in international peer-reviewed journals. As resource person, he has been providing high level technical assistance to the Ministry of Health in formulating various policies, contribution towards technical support for the availability of appropriate paediatric drug formulations for HIV/AIDS, TB, malaria and other infectious diseases, quality assurance and control of medicines on the market and Good Manufacturing Practice and Inspection.